Abstract
Abnormal coagulation and an increased risk of thrombosis are features of severe COVID-19, with parallels proposed with hemophagocytic lymphohistiocytosis (HLH), a life-threating condition associated with hyperinflammation. The presence of HLH was described in severely ill patients during the H1N1 influenza epidemic, presenting with pulmonary vascular thrombosis. We tested the hypothesis that genes causing primary HLH regulate pathways linking pulmonary thromboembolism to the presence of SARS-CoV-2 using novel network-informed computational algorithms. This approach led to the identification of Neutrophils Extracellular Traps (NETs) as plausible mediators of vascular thrombosis in severe COVID-19 in children and adults. Taken together, the network-informed analysis led us to propose the following model: the release of NETs in response to inflammatory signals acting in concert with SARS-CoV-2 damage the endothelium and direct platelet-activation promoting abnormal coagulation leading to serious complications of COVID-19. The underlying hypothesis is that genetic and/or environmental conditions that favor the release of NETs may predispose individuals to thrombotic complications of COVID-19 due to an increase risk of abnormal coagulation. This would be a common pathogenic mechanism in conditions including autoimmune/infectious diseases, hematologic and metabolic disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported by the NSERC Discovery grant RGPIN-2019-04460 (AE), and a grant from McGill Initiative in Computational Medicine (MiCM) and McGill Interdisciplinary Initiative in Infection and Immunity (MI4) (AE and SR). SR is supported by a Chercheur-Boursier Senior salary award from the Fonds de Recherche du Quebec-Sante. KT is supported by a Chercheur-Junior 1 salary award from the Fonds de Recherche du Quebec-Sante.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NO IRB approval was required for this study as the data used was publicly available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All datasets used in this study are publicly available. Moreover, the software GeneList2COVID19 is written in Python, available as an open source tool at GitHub (https://github.com/phoenixding/genelist2covid19). An implementation of the software foRWaRD is available in Python and is freely available on GitHub (https://github.com/ddhostallero/foRWaRD). These GitHub repositories include the source code as well as detailed instructions on how to install and use the methods.
